GlassScriptPhysician profile
Seung Su Lee
NPI 1508423484
$3,105.26
in general payments reported to CMS, 2019-2025
36 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.82 · 2020: $190 · 2021: $228 · 2022: $358 · 2023: $74.55 · 2024: $514 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $531.18 | 2022-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $220.24 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $195.92 | 2022-2025 | |
| Sk Life Science, INC. | $188.29 | 2022-2025 | |
| Lilly USA, LLC | $176.60 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Greenwich Biosciences, INC. | $166.08 | 2019-2021 | |
| Argenx US, INC. | $148.72 | 2024-2025 | Vyvgart Hytrulo |
| Microvention, INC. | $140.73 | 2020 | |
| Pfizer INC. | $128.99 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $128.45 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $104.30 | 2024-2025 | Ultomiris |
| Lundbeck LLC | $84.24 | 2024-2025 | Rexulti, Vyepti |
| Abbvie INC. | $81.18 | 2025 | |
| Neurelis, INC. | $76.78 | 2021-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $64.68 | 2024-2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $61.78 | 2025 | Tanlor |
| Takeda Pharmaceuticals U.S.A., INC. | $53.35 | 2024-2025 | Hyqvia |
| Alnylam Pharmaceuticals INC. | $50.12 | 2024-2025 | Amvuttra |
| Biogen, INC. | $48.92 | 2025 | Leqembi |
| Nevro Corp. | $35.21 | 2021 | |
| Eisai INC. | $35.11 | 2024 | |
| Genentech USA, INC. | $35.03 | 2025 | Ocrevus Zunovo |
| Allergan, INC. | $34.28 | 2021 | |
| Emd Serono, INC. | $33.39 | 2025 | |
| Globus Medical, INC. | $32.97 | 2025 | Senza |
| Harmony Biosciences LLC | $31.77 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.77 | 2022 | |
| Neuropace, INC. | $28.54 | 2023 | |
| Axsome Therapeutics, INC. | $27.02 | 2025 | Symbravo |
| Octapharma USA, INC. | $25.14 | 2025 | Panzyga |
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Chiesi USA, INC. | $20.83 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.66 | 2025 | Crexont |
| Aucta Pharmaceuticals, INC. | $16.07 | 2025 | Motpoly Xr |
| Amgen INC. | $15.97 | 2025 | Uplizna |
| Ani Pharmaceuticals, INC. | $15.90 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seung Su Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.